CAS 2438-72-4: Bufexamac

BUFEXAMAC CRS

Bufexamac

Bufexamac is a non-steroidal antiinflammatory drug that belongs to the class of pyridyl-2-one derivatives. It inhibits matrix metalloproteinase (MMP) activity and has been shown to inhibit the activity of MMP-9 in a statistically significant manner. Bufexamac also binds to DNA, inhibiting bacterial growth by binding to dna binding activity. In addition, bufexamac nanoparticulate compositions have been shown to have uv absorption and can be used for diagnosis. The antioxidative properties of bufexamac may reduce cancer risk and inflammatory skin diseases such as psoriasis. Bufexamac has been shown to be an effective treatment for chronic schizophrenia and other mental illnesses with high body mass index. Further, bufexamac has been found to bind specifically to the enzyme responsible for fragmentation of amyloid precursor protein (APP).

2-(4-Butoxyphenyl)-N-Hydroxyacetamide

Applications Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Bufexamac is a non-steroidal anti-inflammatory drug used topically as well as rectally. Formulations containing Bufexamac is used by many patients with eczematous disorders as an alternative to topical corticosteroids. References Bantscheff, M. et al.: Nature Biotechnol., 29, 255 (2011); Kranke, B. et al.: Cont. Derm., 36, 212 (1997);

Bufexamac (Bufexamic acid) is a COX inhibitor for IFN-α release with anti-inflammatory, analgesic, and antipyretic action.